Table 4 Treatment response and survival in the Phase II intention-to-treat population

From: Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

 

Patients, N =54

% (95% CI)

Overall response rate

CR

0

—

PR

1

1.8

SD

34

63.0

PD

17

31.5

NE

2

3.7

DCR (PR+SD)

35

64.9 (51–77)

OS

Median, months (95% CI)

 

8 (4.8–9.7)

Rates

6 Months

58 (44–70)

 

12 Months

26 (14–40)

 

18 Months

13 (4–26)

PFS

Median, months (95% CI)

 

3.7 (3.2–4.7)

Rates

6 Months

28 (17–40)

 

12 Months

3 (0–13)

  1. Abbreviations: CI=confidence interval; CR=complete response; DCR=disease control rate; NE=not evaluable; OS=overall survival; PD=progressive disease; PFS=progression-free survival; PR=partial response; SD=stable disease.
Back to article page